Fig 2: A Correlation of serum NAMPT levels with ARCO stages. B Correlation of serum NAMPT levels with HHS. C Correlation of serum NAMPT levels with VAS

Fig 3: A ROC curve analysis of serum NAMPT levels with regard to healthy controls vs NONFH cases. B ROC curve analysis of serum NAMPT levels with regard to ARCO 3 vs ARCO 4. C ROC curve analysis of serum NAMPT levels with regard to ARCO 2 vs ARCO 3

Fig 4: Changes in adipokines throughout the intervention. (A) Adiponectin; (B) Leptin; (C) Resistin; (D) Omentin; (E) Vaspin; (F) Visfatin; (G) Apelin; (H) Retinol binding protein 4 (RBP-4); (I) Chemerin; (J) Semaphorin-3c. n = 11 per group, error bars represent a 95% confidence interval (CI). * Significantly different from pre-test; # Significantly different than CG; ^ Significantly different than TG; € Significantly different than SG.

Fig 5: Impact of BTKi bridging therapy on serum nicotinamide phosphoribosyltransferase (NAMPT) and programmed cell death 1 (PD-1) expression in lymphoma patient groups. (A–D): NAMPT levels before and after BTKi therapy, showing significant reductions in the ≥2 months group, the ≥2 months + Richter group, and the CR+PR group; no significant changes in <2 months, DLBCL, Richter, <2 months + DLBCL, and SD+PD groups. (E–H): PD-1 expression in CD3+ T cells before and after BTKi therapy, showing significant reductions in the ≥2 months group, the Richter group, the ≥2 months + Richter group, and the CR+PR group; no significant changes in <2 months, DLBCL, and <2 months + DLBCL groups.